Illumina, Inc.
IndexS&P 500 P/E50.98 EPS (ttm)4.58 Insider Own0.10% Shs Outstand157.00M Perf Week5.92%
Market Cap34.18B Forward P/E45.03 EPS next Y5.19 Insider Trans-4.46% Shs Float156.54M Perf Month-30.54%
Income700.00M PEG36.41 EPS next Q0.65 Inst Own89.10% Short Float1.18% Perf Quarter-29.05%
Sales4.66B P/S7.34 EPS this Y13.90% Inst Trans0.48% Short Ratio1.94 Perf Half Y-39.04%
Book/sh69.39 P/B3.37 EPS next Y25.30% ROA5.20% Target Price371.38 Perf Year-38.41%
Cash/sh9.68 P/C24.14 EPS next 5Y1.40% ROE7.50% 52W Range208.35 - 526.00 Perf YTD-38.56%
Dividend- P/FCF164.34 EPS past 5Y10.10% ROI-2.00% 52W High-55.56% Beta1.08
Dividend %- Quick Ratio1.50 Sales past 5Y13.50% Gross Margin68.80% 52W Low12.19% ATR15.77
Employees9800 Current Ratio1.80 Sales Q/Q11.90% Oper. Margin-2.90% RSI (14)29.02 Volatility6.46% 5.59%
OptionableYes Debt/Eq0.16 EPS Q/Q-45.90% Profit Margin15.00% Rel Volume1.55 Prev Close233.56
ShortableYes LT Debt/Eq0.11 EarningsMay 05 AMC Payout0.00% Avg Volume951.11K Price233.74
Recom2.80 SMA20-18.74% SMA50-26.80% SMA200-38.85% Volume1,468,405 Change0.08%
Jan-18-22Upgrade Stifel Hold → Buy $480
Jan-11-22Upgrade Barclays Underweight → Equal Weight
Jan-07-22Upgrade BofA Securities Underperform → Neutral
Jan-06-22Resumed Piper Sandler Overweight $450
Jan-06-22Resumed Morgan Stanley Equal-Weight $425
Oct-15-21Resumed Cowen Outperform $550
Aug-19-21Downgrade SVB Leerink Outperform → Mkt Perform $425
Jun-01-21Upgrade Evercore ISI Underperform → In-line $400
Mar-31-21Upgrade Canaccord Genuity Hold → Buy $445
Mar-31-21Downgrade Atlantic Equities Overweight → Neutral $390
Mar-03-21Initiated Barclays Underweight $325
Dec-22-20Upgrade Piper Sandler Neutral → Overweight $340 → $415
Dec-17-20Upgrade BTIG Research Neutral → Buy $410
Oct-13-20Downgrade Guggenheim Buy → Neutral
Sep-30-20Initiated Atlantic Equities Overweight $355
Sep-29-20Downgrade Wolfe Research Outperform → Peer Perform
Sep-22-20Downgrade UBS Buy → Neutral $390 → $285
Sep-22-20Downgrade Stifel Buy → Hold $380 → $280
Sep-21-20Upgrade Guggenheim Neutral → Buy $345
Sep-21-20Downgrade JP Morgan Overweight → Neutral $390 → $280
May-15-22 10:35AM  
May-12-22 11:00AM  
May-11-22 10:02AM  
May-09-22 02:13PM  
May-06-22 04:46PM  
May-05-22 05:45PM  
May-03-22 10:39AM  
May-02-22 10:01AM  
Apr-29-22 09:02AM  
Apr-28-22 04:05PM  
Apr-27-22 09:03AM  
Apr-25-22 02:41PM  
Apr-24-22 05:34PM  
Apr-22-22 07:52AM  
Apr-20-22 10:13AM  
Apr-19-22 09:04AM  
Apr-18-22 01:01PM  
Apr-14-22 04:05PM  
Apr-13-22 10:42AM  
Apr-12-22 01:46PM  
Apr-11-22 10:29AM  
Apr-07-22 12:46PM  
Apr-06-22 09:04AM  
Apr-05-22 09:06AM  
Apr-01-22 05:52PM  
Mar-24-22 04:16PM  
Mar-23-22 09:31AM  
Mar-22-22 12:01PM  
Mar-18-22 12:31PM  
Mar-16-22 02:06PM  
Mar-15-22 11:46AM  
Mar-14-22 10:02AM  
Mar-10-22 12:48PM  
Mar-09-22 10:02AM  
Mar-08-22 10:02AM  
Mar-07-22 10:01AM  
Mar-04-22 11:02AM  
Mar-03-22 12:05PM  
Mar-01-22 01:16PM  
Feb-28-22 10:00AM  
Feb-25-22 08:00AM  
Feb-24-22 10:00AM  
Feb-22-22 10:02AM  
Feb-21-22 04:05PM  
Feb-18-22 01:06PM  
Feb-17-22 10:00AM  
Feb-16-22 11:06AM  
Feb-15-22 11:00AM  
Feb-14-22 10:00AM  
Feb-11-22 10:00AM  
Feb-10-22 05:54PM  
Feb-09-22 09:13AM  
Feb-08-22 01:38PM  
Feb-07-22 01:38PM  
Feb-04-22 05:38PM  
Feb-03-22 04:05PM  
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has collaboration agreements with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer; LetsGetChecked to track COVID-19 variants in California; and Merck & Co., Inc. to develop and commercialize tests that identify genetic mutations used in the assessment of homologous recombination deficiency. The company was incorporated in 1998 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dadswell CharlesSVP & General CounselApr 28Sale300.13368110,4487,427May 02 04:54 PM
Hoyt Aimee LSVP, Chief People OfficerApr 12Sale350.512,474867,1735,342Apr 14 04:33 PM
Febbo Phillip G.SVP Chief Medical OfficerApr 06Sale360.011,988715,7005,774Apr 07 04:19 PM
Dadswell CharlesSVP & General CounselMar 28Sale342.83368126,1617,795Mar 30 07:02 PM
Hoyt Aimee LSVP, Chief People OfficerFeb 22Option Exercise0.003,42106,678Feb 24 05:36 PM
TOUSI SUSAN HSVP, Chief Commercial OfficerFeb 22Option Exercise0.004,561043,891Feb 24 05:42 PM
deSouza Francis APresident and CEOFeb 22Option Exercise0.0019,383088,587Feb 24 05:43 PM
Febbo Phillip G.SVP Chief Medical OfficerFeb 22Option Exercise0.002,85105,866Feb 24 05:32 PM
SAMAD SAMSVP and CFOFeb 22Option Exercise0.004,561011,023Feb 24 05:39 PM
Pegels Kevin CarlChief of Global OperationsFeb 22Option Exercise0.001,06505,910Feb 24 05:38 PM
GOSWAMI JOYDEEPSVP Corp Business DevelopmentFeb 22Option Exercise0.003,97907,824Feb 24 05:34 PM
Dadswell CharlesSVP & General CounselFeb 22Option Exercise0.004,56107,889Feb 24 05:30 PM
TOUSI SUSAN HSVP, Chief Commercial OfficerJan 12Sale425.00800340,00039,274Jan 13 04:48 PM
TOUSI SUSAN HSVP, Chief Commercial OfficerDec 28Sale387.0610038,70640,074Dec 30 04:10 PM
Dadswell CharlesSVP & General CounselDec 22Sale380.29322122,4533,283Dec 23 05:37 PM
TOUSI SUSAN HSVP, Chief Commercial OfficerDec 08Sale375.0010037,50040,174Dec 09 04:32 PM
Dadswell CharlesSVP, General CounselNov 22Sale377.86314118,6483,605Nov 24 04:16 PM
Aravanis AlexanderSVP, Chief Technology OfficerNov 12Sale386.35361139,4724,127Nov 16 04:52 PM
Febbo Phillip G.SVP Chief Medical OfficerNov 08Sale406.831,000406,8303,015Nov 09 04:59 PM
Aravanis AlexanderSVP, Chief Technology OfficerNov 02Sale412.782,9261,207,8014,679Nov 04 06:11 PM
TOUSI SUSAN HSVP, Chief Commercial OfficerOct 28Sale414.3510041,43541,256Nov 01 04:33 PM
Aravanis AlexanderSVP, Chief Technology OfficerOct 26Sale423.002,9261,237,6987,605Oct 28 05:27 PM
Dadswell CharlesSVP & General CounselOct 22Sale411.00314129,0544,658Oct 26 04:48 PM
Aravanis AlexanderSVP, Chief Technology OfficerOct 19Sale411.822,9261,204,97210,531Oct 21 05:50 PM
Aravanis AlexanderSVP, Chief Technology OfficerOct 12Sale409.212,9261,197,35013,457Oct 14 06:29 PM
TOUSI SUSAN HSVP, Chief Commercial OfficerSep 28Sale418.0410041,80441,356Sep 30 04:04 PM
Dadswell CharlesSVP & General CounselSep 22Sale436.69314137,1214,972Sep 23 04:24 PM
TOUSI SUSAN HSVP, Chief Commercial OfficerAug 30Sale463.50300139,05041,456Sep 01 07:15 PM
Dadswell CharlesSVP & General CounselAug 23Sale489.10314153,5775,286Aug 25 04:40 PM
TOUSI SUSAN HSVP, Chief Commercial OfficerAug 04Sale500.001,000500,00041,756Aug 05 04:22 PM
Hoyt Aimee LSVP, Chief People OfficerAug 04Sale500.00372186,0003,757Sep 08 07:36 PM
TOUSI SUSAN HSVP, Chief Commercial OfficerJul 28Sale486.41300145,92342,743Jul 29 04:34 PM
Dadswell CharlesSVP & General CounselJul 22Sale482.23314151,4205,576Jul 26 04:57 PM
Aravanis AlexanderSVP, Chief Technology OfficerJul 07Sale477.59539257,4214,679Jul 07 06:26 PM
TOUSI SUSAN HSVP, Chief Commercial OfficerJun 28Sale478.95300143,68543,043Jun 30 05:27 PM
Hoyt Aimee LSVP, Chief People OfficerJun 24Sale475.00500237,5004,111Sep 08 07:36 PM
Dadswell CharlesSVP & General CounselJun 22Sale461.01314144,7575,890Jun 24 05:41 PM
Febbo Phillip G.SVP Chief Medical OfficerJun 11Sale447.591,000447,5884,461Jun 14 05:50 PM
DORSA CAROLINEDirectorJun 10Sale450.001,000450,0008,501Jun 14 05:48 PM
Hoyt Aimee LSVP, Chief People OfficerJun 10Sale450.00500225,0004,611Sep 08 07:36 PM
Dadswell CharlesSVP & General CounselMay 24Sale403.04314126,5556,204May 26 04:50 PM
TOUSI SUSAN HSVP, Chief Commercial OfficerMay 20Sale400.00500200,00043,343May 24 04:43 PM
FLATLEY JAY TDirectorMay 18Sale379.534,0001,518,120148,933May 20 04:51 PM